307 related articles for article (PubMed ID: 9351529)
1. Prophylaxis in haemophilic children.
Liesner RJ
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S7-10. PubMed ID: 9351529
[TBL] [Abstract][Full Text] [Related]
2. Experience with prophylaxis in Sweden.
Nilsson IM
Semin Hematol; 1993 Jul; 30(3 Suppl 2):16-9. PubMed ID: 8367738
[No Abstract] [Full Text] [Related]
3. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
[TBL] [Abstract][Full Text] [Related]
4. Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy.
Lindvall K; Astermark J; Björkman S; Ljung R; Carlsson KS; Persson S; Berntorp E
Haemophilia; 2012 Nov; 18(6):855-9. PubMed ID: 22681244
[TBL] [Abstract][Full Text] [Related]
5. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients.
Nagel K; Walker I; Decker K; Chan AK; Pai MK
Haemophilia; 2011 Nov; 17(6):872-4. PubMed ID: 21342368
[TBL] [Abstract][Full Text] [Related]
6. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
Ahnström J; Berntorp E; Lindvall K; Björkman S
Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
[TBL] [Abstract][Full Text] [Related]
7. Relationship between factor VIII replacement therapy and joint damage in severe haemophilia.
Lowe GD
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S3-5. PubMed ID: 9351528
[TBL] [Abstract][Full Text] [Related]
8. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China.
Wu R; Luke KH; Poon MC; Wu X; Zhang N; Zhao L; Su Y; Zhang J
Haemophilia; 2011 Jan; 17(1):70-4. PubMed ID: 20579111
[TBL] [Abstract][Full Text] [Related]
9. Use of implantable venous access devices in children with severe hemophilia: benefits and burden.
Van Dijk K; Van Der Bom JG; Bax KN; Van Der Zee DC; Van Den Berg MH
Haematologica; 2004 Feb; 89(2):189-94. PubMed ID: 15003894
[TBL] [Abstract][Full Text] [Related]
10. [Prophylactic treatment with clotting factor to prevent joint damage in patients with severe haemophilia: costs versus benefits].
Roosendaal G; Lafeber FP
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2606-8. PubMed ID: 18161260
[TBL] [Abstract][Full Text] [Related]
11. Changing paradigm of prophylaxis with longer acting factor concentrates.
Carcao M
Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
[TBL] [Abstract][Full Text] [Related]
12. Central venous access catheters in children with haemophilia.
Blanchette VS; al-Musa A; Stain AM; Filler RM; Ingram J
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S39-44. PubMed ID: 8735796
[TBL] [Abstract][Full Text] [Related]
13. Central venous access devices in children with hemophilia: an update.
Blanchette VS; Al-Musa A; Stain AM; Ingram J; Fille RM
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S11-4. PubMed ID: 9351530
[TBL] [Abstract][Full Text] [Related]
14. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
[TBL] [Abstract][Full Text] [Related]
15. The current status of prophylactic replacement therapy in children and adults with haemophilia.
Ljung R; Gretenkort Andersson N
Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
[TBL] [Abstract][Full Text] [Related]
16. Dose and outcome of care in haemophilia--how do we define cost-effectiveness?
Fischer K; Van den Berg HM; Thomas R; Kumar S; Poonnoose P; Viswabandya A; Mathews V; Kavitha ML; Bhattacharji S; Srivastava A
Haemophilia; 2004 Oct; 10 Suppl 4():216-20. PubMed ID: 15479401
[TBL] [Abstract][Full Text] [Related]
17. Adherence to prophylactic infusions of factor VIII or factor IX for haemophilia.
Thornburg CD; Pipe SW
Haemophilia; 2006 Mar; 12(2):198-9. PubMed ID: 16476098
[No Abstract] [Full Text] [Related]
18. Recombinant factor VIII in hemophilia A: the Canadian experience.
Blanchette VS
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
[TBL] [Abstract][Full Text] [Related]
19. Prevention of haemophilic synovitis: prophylaxis.
Lee CA
Haemophilia; 2007 Nov; 13 Suppl 3():20-5. PubMed ID: 17822517
[TBL] [Abstract][Full Text] [Related]
20. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens.
Berntorp E
Haemophilia; 2009 Nov; 15(6):1219-27. PubMed ID: 19659939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
